Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Kazia Therapeutics ( (KZIA) ) has shared an announcement.
On February 20, 2025, Kazia Therapeutics announced a research grant from The Michael J. Fox Foundation to fund studies with The Hebrew University of Jerusalem. The grant will support preclinical studies to explore the therapeutic potential of paxalisib for Parkinson’s disease. The research focuses on understanding the impact of paxalisib on Parkinson’s-related pathways and its potential to address the disease’s underlying pathophysiology. This grant and collaboration could strengthen Kazia’s position in developing treatments beyond oncology, potentially broadening its impact on neurodegenerative diseases.
More about Kazia Therapeutics
Kazia Therapeutics Limited is an oncology-focused drug development company based in Sydney, Australia. The company specializes in developing treatments for brain cancer, with its lead program being paxalisib, an investigational inhibitor of the PI3K / Akt / mTOR pathway designed to penetrate the brain. This drug has been involved in multiple clinical trials targeting various forms of brain cancer, including glioblastoma and brain metastases. Kazia is also developing EVT801, another therapeutic agent aimed at a broad range of tumor types.
YTD Price Performance: -48.85%
Average Trading Volume: 1,937,897
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $5.03M
For a thorough assessment of KZIA stock, go to TipRanks’ Stock Analysis page.
